Skip to main content
. 2010 Jul 28;15(8):845–851. doi: 10.1634/theoncologist.2010-0030

Figure 1.

Figure 1.

Overall survival, disease-free survival, freedom from distant metastases, and local control from the National Cancer Institute #5642 study (bevacizumab group). Shown are Kaplan–Meier estimates of disease-free survival (A), overall survival (B), freedom from distant metastases (C), and local control (D).